Evidence mapPaperPMID 38250336Full record

ArticleSexual medicine2023

Can atherogenic indices and the triglyceride-glucose index be used to predict erectile dysfunction?

Murat Sambel, Abdullah Erdogan, Volkan Caglayan, Sinan Avci, Sahin Kilic, Halil Emre Yildiz, Ercument Keskin

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Sexual medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07479901 (Investigation of the Effect of the Atherogenic Index on the Therapeutic Response to Tadalafil in Patients With Vascular Erectile Dysfunction), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07479901 active not recruitingnot on this mapstarted 2025, after this paper: background citation

Investigation of the Effect of the Atherogenic Index on the Therapeutic Response to Tadalafil in Patients With Vascular Erectile Dysfunction

Typeobservational_patient_registrySponsorTaksim Egitim ve Arastirma HastanesiRan2025 to 2027Enrolled132ConditionsErectile Dysfunction Vascular Erectile Dysfunction Atherogenic Dyslipidemia
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Murat SambelDepartment of Urology, Antalya Training and Research Hospital, Varlik 07100, Antalya, Turkey.ORCID https://orcid.org/0000-0002-3069-7078
Abdullah ErdoganDepartment of Urology, Bursa City Hospital, Nilufer 16110, Bursa, Turkey.
Volkan CaglayanDepartment of Urology, Bursa City Hospital, Nilufer 16110, Bursa, Turkey.
Sinan AvciDepartment of Urology, Bursa City Hospital, Nilufer 16110, Bursa, Turkey.
Sahin KilicDepartment of Urology, Antalya Training and Research Hospital, Varlik 07100, Antalya, Turkey.
Halil Emre YildizDepartment of Urology, Mus State Hospital, 49100, Mus, Turkey.
Ercument KeskinDepartment of Urology, Mengucek Gazi Education and Research Hospital, Erzincan Binali Yildirim University, 24002, Erzincan, Turkey.
Bursa Technical University · TRAntalya Eğitim ve Araştırma Hastanesi · TRErzincan Binali Yıldırım University · TRSivas State Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Atherosclerosis and insulin resistance play an important role in the development of erectile dysfunction (ED), and few studies have comprehensively evaluated more specific indicators like atherogenic indices and the triglyceride-glucose (TyG) index in the assessment of ED. Aim: This study aimed to reveal the role of atherogenic indices (atherogenic index of plasma [AIP], Castelli risk index-1/2 [CRI-1/2], and atherogenic coefficient [AC]) based on plasma lipid ratios, which have been used as more sensitive indicators of atherosclerosis in recent years, and the TyG index, a practical indicator of insulin resistance, in predicting vasculogenic ED. Methods: The study included a total of 199 patients who met the inclusion criteria and a total of 51 control subjects without ED complaints according to the International Index of Erectile Function (IIEF-5) scores (>21) between May 2021 and October 2022. For all participants, the demographic and biochemical parameters were evaluated, and atherogenic indices, namely CRI-1 (total cholesterol/high-density lipoprotein [HDL]), CRI-2 (LDL/HDL) AIP [log10(triglycerides/HDL)], and AC (non-HDL/HDL), as well as the TyG index [Ln {fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2}] were calculated. Outcomes: The TyG index, which is an indicator of insulin resistance, and atherogenic indices such as CRI-1, AIP, and AC were significantly associated with ED, and especially AIP and the TyG index seem to be more important in the evaluation of ED. Results: According to the univariate analysis, the patient group had significantly higher CRI-1 (5.3 ± 1.4 vs 4.7 ± 1.3; Clinical Implications: The use of atherogenic indices and TyG index in daily urology practice can help physicians in the diagnosis and follow-up of ED. Strengths and Limitations: The lack of sex hormone-binding globulin and free testosterone levels represents a limitation of our study. Another limitation is that the severity of ED was determined using the IIEF-5 scores, rather than a more objective method, such as penile artery ultrasound. Conclusion: Atherogenic indices and the TyG index can be used as inexpensive and practical markers to predict the severity of arteriogenic ED.

Indexed as

atherogenic indicesendothelial dysfunctionerectile dysfunctioninsulin resistancetriglyceride-glucose index

Identifiers

PMID38250336
PMCPMC10799712
OpenAlexW4391058276

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.